Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series

Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series

Background: Patients with borderline-resectable pancreatic ductal adenocarcinoma (BR-PDAC) have historically poor survival, even after curative pancreatic resection and adjuvant chemotherapy. Emerging evidence suggests that neoadjuvant chemoradiation (NCR) improves R0 resection rates in BR-PDAC pati...

Full description

Bibliographic Details
Main Authors: Rachna Gorbudhun, Pranav H. Patel, Eve Hopping, Joseph Doyle, Georgios Geropoulos, Vasileios K. Mavroeidis, Sacheen Kumar, Ricky H. Bhogal
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
pancreatic cancer
neoadjuvant treatment
Whipple’s surgery
pancreatic resection
Online Access:https://www.mdpi.com/2072-6694/14/19/4678

Internet

https://www.mdpi.com/2072-6694/14/19/4678

Similar Items